DNA Testing Market Worth $10.04 Billion By 2022: Grand View Research, Inc.

Jan 12, 2016, 05:00 ET from Grand View Research, Inc.

SAN FRANCISCO, January 12, 2016 /PRNewswire/ --

Global DNA testing market is anticipated to reach USD 10.04 billion by 2022, according to a new study by Grand View Research Inc. Rise in developments in the field of genome sequencing and personalized DNA level diagnostic applications, a considerable growth in the number of patented research initiatives by the government and government funded projects are factors expected to drive demand during the forecast period.

Browse full research report with TOC on "DNA Testing Market Analysis By Technology (DNA Diagnostics, Microarray Based, PCR Based, In-situ Hybridization, NGS DNA Diagnosis), By Application (Pre-natal DNA Carrier Screening, Pre-implantation Diagnosis, Newborn Genetic Screening, Infectious Disease Diagnostics (HBV, HCV, HIV, TB, CT/NG, HPV, & MRSA), Oncology Diagnostics & Histopathology, Identity Diagnostics & Forensics, Pharmacogenomics Diagnostic Testing, & Drug Metabolism/P450 Effects), And Segment Forecasts To 2022" at: http://www.grandviewresearch.com/industry-analysis/dna-testing-market                                                                                                                                                                

Introduction of novel technologies for genome profiling are expected to boost progress of this industry over the forecast period. Furthermore, increasing incidences of chronic oncology and infectious diseases that depend on DNA prototyping for treatment and diagnosis using personalized medicine are anticipated to significantly raise demand for DNA diagnostics/testing based research thereby propelling industrial growth in the coming years. Increasing demand for prenatal testing and in-vitro fertilization that subsequently leads to rise in demand for DNA diagnostics/testing is also attributive towards expected progress in this market.

Further key findings from the report suggest: 

  • PCR based diagnosis accounted for the largest share of the market revenue in 2014 as a result of higher preference rate coupled with higher availability of products and reagent kits of this segment.
  • Next generation sequencing application for DNA testing is estimated to witness significant progress with a double digit CAGR of over 16% amongst the other technology segments due to presence of significant advantages offered by this technique of DNA identification and testing.
  • Infectious disease diagnostics accounted for the largest market share in 2014 due to higher incidence rate of various infectious disorders which subsequently raises the demand for in-vitro nucleic acid based diagnostic tests for diagnosis and monitoring of disease progression.
  • There are diverse applications of DNA testing market out of which oncology diagnostics and histopathology is estimated to register lucrative growth over the forecast period. Factors attributing for considerable growth potential in this segment include identification of cancer causing genes & associated research, and facilitation in mutation detection
  • North America dominated the market in 2014, with revenue estimated at over USD 2,600 million. Presence of sophisticated healthcare infrastructure, rising incidence of genetic abnormalities, favorable government initiatives with respect to genetic diagnosis and its application in in-vitro fertilization are major factors driving growth of this region.
  • Asia Pacific is anticipated to witness lucrative growth as a result of developments in health care infrastructure in this region coupled with presence of significant number of target population that is suffering with chronic as well as acute disorders. Government initiatives taken up herein are also attributive to influence sector growth to a great extent.
  • Key participants of DNA testing industry include Abbott Laboratories, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Applied Biosystems Group, Cepheid Inc., Transgenomic Inc., Siemens Healthcare, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Alere Inc, Affymetrix Inc., Hologic, Dako, and 454 Life Sciences.

Grand View Research has segmented DNA testing market on the basis of technology, application, and region:

  • Global DNA Diagnostics/Testing Technology Outlook (Revenue, USD Million, 2012 - 2022) 
    • Microarrays based diagnostics
    • PCR based diagnostics
    • In-situ hybridization diagnostics
    • NGS DNA diagnosis
  • Global DNA Diagnostics/Testing Application Outlook (Revenue, USD Million, 2012 - 2022) 
    • Prenatal DNA Carrier Screening
    • Preimplantation Diagnosis
    • Newborn Genetic Screening
    • Infectious Disease Diagnostics
      • HBV Diagnostic
      • HCV Diagnostic
      • HIV Diagnostic
      • TB Diagnostic
      • CT/NG Diagnostic
      • HPV Diagnostic
      • MRSA Diagnostic
      • Others
    • Oncology Diagnostics & Histopathology
    • Identity Diagnostics & Forensics
    • Pharmacogenomics Diagnostic Testing
    • Drug Metabolism & P450 effects
    • Others
  • DNA Diagnostics/Testing Regional Outlook (Revenue, USD Million, 2012 - 2022) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • Japan
      • China
    • Latin America
      • Brazil
      • Mexico
    • MEA
      • South Africa

Browse related reports by Grand View Research: 

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Read Our Blogs - mediafound.org, ni2014.org  

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: http://www.grandviewresearch.com  

SOURCE Grand View Research, Inc.